What Should CVS Stock Investors Be Watching Now?
If you own CVS Health (CVS), the primary focus shifts from 2026 execution toward potential headwind variables heading into 2027. Management raised its 2026 earnings outlook on its fiscal Q2 2026 call in August. It also gave an early read on 2027, a quarter sooner than usual. One warning in that read came with no number. Over the past three months, the shares lost 15.2%, while the S&P 500 gained 5.0%. What is the 2027 problem CVS would not put a number on?
CVS Expects Its 340B Business To Weigh On 2027
The problem is the 340B business, and management raised it itself. CVS felt some pressure in that business in fiscal Q2 2026, as the program’s environment keeps changing. Drug makers are putting limits on the groups the program covers. Management said those limits led to some of the second-quarter hit.
Management expects that pressure to continue. It said it expects the 340B business to be a drag on its pharmacy services business in 2027. A question on that same call described the program as a moving target within D.C. Management would not put a size on the 340B hit. So you have to size the business around it yourself.
How Big Is The CVS Business Around That Hit?
The business around it is large, but the 340B part has no size. Management said in the fiscal Q2 2026 call that it was not commenting on 340B sizing specifically. It added that its plans to handle it are still being built.
Management put the drag in its pharmacy services business. Management did not say which reported segment holds the 340B business. Health Services, the segment that serves pharmacy clients, is the closest reported measure. Management said continued price improvements for pharmacy clients partly offset the segment’s revenue growth. That segment had revenue of $190.4 billion in fiscal 2025, up 9.7% from a year earlier. In fiscal Q2 2026, its adjusted operating income, a profit measure the company adjusts for one-time items, was over $1.7 billion. That was up 10% from a year earlier.
Some of that quarter was borrowed from later, though. Management said value it had expected in the second half of the year arrived early, in the second quarter. On the other side, management said its specialty pharmacy business continues to perform exceptionally well.
On earnings, the price leaves no extra cushion. CVS trades at 22.5 times its past year’s earnings, level with 22.4 for the S&P 500. The three-month decline occurred even as management raised full-year 2026 earnings guidance, leaving you to weigh the shares’ drop against those unquantified 2027 variables. With no size for the 340B hit, past falls at least show how far the stock can swing in a bad stretch.
What Would A Bad Stretch Cost CVS Stock Investors?
A bad stretch has sometimes cost CVS holders far more than the market. During the 2023 SVB Regional Banking Crisis, the stock fell 25% from peak to trough, against 6.7% for the S&P 500. A $10,000 position falling that far would have been worth about $7,500 at the low. Not every shock hit CVS harder, though. In the 2025 US Tariff Shock, the stock fell 8.6%, while the index fell 19.0%. Neither shock was about 340B, so they show how far the stock can swing, not what this risk could cost.
The 340B risk looks real but slow. Management frames it as a 2027 drag. The pressure felt so far did not stop it raising the 2026 outlook. Management still expects adjusted earnings per share to grow at a mid-teens yearly rate from 2025 through 2028. A large size for the 340B hit, or a cut to that growth plan, would confirm the worry. Health Services profit that keeps growing without the early boost would ease it.
The fiscal Q3 2026 report is the next place to see which way that profit is heading. What you need to watch is whether Health Services profit can absorb the 340B drag and keep the company tracking toward that mid-teens EPS growth goal.
How To Act On CVS?
